Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.

Cancer science - 1 Mar 2022

Koga Takamasa, Suda Kenichi, Mitsudomi Tetsuya

Abstract excerpt

Molecular targeted therapies are the standard of care for front-line treatment of metastatic non-small-cell lung cancers (NSCLCs) harboring driver gene mutations. However, despite the initial dramatic responses, the emergence of acquired resistance is inevitable. Acquisition of secondary mutations in the target gene (on-target resistance) is one of the major mechanisms of resistance. The mouse pro-B cell line...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line
Share to Drug Resistance, Neoplasm
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Models, Biological

Share to Molecular Targeted Therapy

Share to Oncogene Proteins

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 34997674
DOI: 10.1111/cas.15263
PMCID: PMC8898722

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.PMID 34997674Read ↗

In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial.Semantic proximity Read ↗

Analysis of acquired mutations in transgenes arising in Ba/F3 transformation assays: findings and recommendations.Semantic proximity Read ↗

Drug-sensitive FGFR3 mutations in lung adenocarcinoma.Semantic proximity Read ↗

APOBEC3A drives acquired resistance to targeted therapies in non-small cell lung cancerSemantic proximity Read ↗

Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung CancerSemantic proximity Read ↗

An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations.Semantic proximity Read ↗

An immunogenic model of KRAS-mutant lung cancer for study of targeted therapy and immunotherapy combinationsSemantic proximity Read ↗

Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.Semantic proximity Read ↗

ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.Semantic proximity Read ↗

Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.Semantic proximity Read ↗

IGFBP3 Modulates Lung Tumorigenesis and Cell Growth through IGF1 SignalingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.